Monday, 23 September 2019

Takeda sells surgical patch to Ethicon for $400M

13 May 2019 | News

Ethicon will acquire the assets and licenses that support the manufacturing, licensing and commercialization of TachoSil

image credit- mpo-mag.com

image credit- mpo-mag.com

Japan headquartered Takeda Pharma has entered into an agreement to sell TachoSil®, a surgical patch designed to achieve safe, fast and reliable bleeding control, to Ethicon, a subsidiary of Johnson & Johnson. Upon close, approximately 80 employees will transition to Ethicon. 

As part of this deal, Takeda will receive $400 million upfront in cash from Ethicon.

Takeda recorded full year adjusted net sales for TachoSil® of approximately $155 million in the fiscal year ended March 31, 2018.

Under the terms of the agreement, upon close, Ethicon will acquire the assets and licenses that support the manufacturing, licensing and commercialization of TachoSil®, while Takeda will maintain ownership of the manufacturing facility in Linz, Austria.

Takeda has entered into a long-term manufacturing services agreement, under which it will continue to manufacture TachoSil® products and supply them to Ethicon.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls